Opiant Pharmaceuticals, Inc. Reports Second Quarter 2018 Financial Results and Provides Corporate Update
August 09, 2018 16:01 ET
|
Opiant Pharmaceuticals, Inc.
SANTA MONICA, Calif., Aug. 09, 2018 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing pharmacological treatments for...
Opiant Pharmaceuticals to Report Second Quarter 2018 Financial Results and Host Conference Call and Webcast on Thursday, August 9
August 02, 2018 08:00 ET
|
Opiant Pharmaceuticals, Inc.
SANTA MONICA, Calif., Aug. 02, 2018 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ:OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions...
Opiant Pharmaceuticals Announces Receipt of First Tranche from National Institutes of Health Grant for Development of OPNT003, Intranasal Nalmefene, for Treatment of Opioid Overdose
June 25, 2018 16:05 ET
|
Opiant Pharmaceuticals, Inc.
Initial $500,000 to be Utilized to Advance the Development of OPNT003 SANTA MONICA, Calif., June 25, 2018 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ:OPNT), a specialty...
Opiant Pharmaceuticals Appoints Biotech and Pharmaceutical Industry Veteran Richard Daly to Board of Directors
June 12, 2018 08:00 ET
|
Opiant Pharmaceuticals, Inc.
SANTA MONICA, Calif., June 12, 2018 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ:OPNT), a specialty pharmaceutical company developing pharmacological treatments for...
Opiant Pharmaceuticals to Participate in Opioid Panel at the BIO International Convention
June 04, 2018 16:05 ET
|
Opiant Pharmaceuticals, Inc.
SANTA MONICA, Calif., June 04, 2018 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ:OPNT), a specialty pharmaceutical company developing pharmacological treatments for...
Opiant Pharmaceuticals to Participate in The American Society of Clinical Psychopharmacology 2018 Annual Meeting
May 29, 2018 08:00 ET
|
Opiant Pharmaceuticals, Inc.
Company’s Chief Scientific Officer, Phil Skolnick, Ph.D., to Receive ASCP’s “Donald Klein Lifetime Achievement Award” SANTA MONICA, Calif., May 29, 2018 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals,...
Opiant Pharmaceuticals, Inc. Reports First Quarter 2018 Financial Results and Provides Corporate Update
May 08, 2018 16:05 ET
|
Opiant Pharmaceuticals, Inc.
SANTA MONICA, Calif., May 08, 2018 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ:OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions,...
Opiant Pharmaceuticals To Host Key Opinion Leader Meeting on Medications for Addictions and Related Disorders
May 03, 2018 08:00 ET
|
Opiant Pharmaceuticals, Inc.
Key Opinion Leader Luncheon to Take Place in New York City on May 10 SANTA MONICA, Calif., May 03, 2018 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ:OPNT), a specialty...
Opiant Pharmaceuticals Awarded Grant of Approximately $7.4 Million from the National Institutes of Health for Development of OPNT003, Intranasal Nalmefene, for Treatment of Opioid Overdose
April 18, 2018 08:00 ET
|
Opiant Pharmaceuticals, Inc.
Grant Expected to Fund Development of OPNT003 to NDA Ready Stage SANTA MONICA, Calif., April 18, 2018 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ:OPNT), a specialty...
Opiant Pharmaceuticals, Inc. to Present a Corporate Overview at the Oppenheimer 28th Annual Healthcare Conference
March 19, 2018 16:05 ET
|
Opiant Pharmaceuticals, Inc.
SANTA MONICA, Calif., March 19, 2018 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ:OPNT), a specialty pharmaceutical company developing pharmacological treatments for...